New drug firsekibart takes on anakinra in Still's disease showdown

NCT ID NCT07191444

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two medications, firsekibart and anakinra, to see which works better and is safer for people with Adult-Onset Still's disease (AOSD). The trial will enroll 20 adults aged 18 to 75 who have been diagnosed with AOSD. The main goal is to see how many patients achieve inactive disease after 24 weeks of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STILL'S DISEASE, ADULT-ONSET are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult-onset Still disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STILL'S DISEASE, ADULT-ONSET

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••